Cellnovo expands its organisation
October 09 2015 - 1:30AM
Business Wire
- Cellnovo Executive Chairman to
transition to Non-Executive Chairman
- Sophie Baratte appointed CEO
- Company expands management team
Regulatory News:
Cellnovo Group (“Cellnovo”) (Paris:CLNV), a medical technology
company that has developed and markets the first connected
all-in-one diabetes management system, today announced that Eric
Beard will transition from CEO and Executive Chairman of the board
of directors to Non-Executive Chairman, effective October 1st. Mr.
Beard has served as Chairman on the company’s board of directors
since 2011 and was appointed Executive Chairman in September
2012.
As part of its executive succession plan, Cellnovo appointed
Sophie Baratte as its CEO effective October 1st, 2015. She has a
distinguished career in healthcare having held senior positions at
Johnson & Johnson, Sorin, CIT and Lifecell. She has extensive
experience in sales and marketing and particularly in bringing
innovative technologies to market. Ms Baratte joined Cellnovo in
November 2014 as Chief Business Officer. She was appointed CEO of
Cellnovo Ltd, the operations arm of the Group, in April 2015.
“Today’s announcement reflects the board’s confidence in the
progress of our business,” said Raphael Wisniewski, director. “Eric
has been instrumental in establishing Cellnovo as a leader in the
field of insulin delivery and diabetes management. We are pleased
that he will continue to lead the board and work with management to
sustain our momentum.”
Eric Beard, Chairman of Cellnovo, said, “I am delighted to
announce Sophie as CEO. Sophie and I have worked together before
she joined Cellnovo and she is a well-rounded executive with great
operations experience. I am also very pleased that I will continue
my association with Cellnovo as Chairman and I look forward to
contributing to the future success of the company in that
role.”
Cellnovo also announced the expansion of its management team
with several new key hires:
- Myriam Desmet is appointed Vice
President Regulatory Affairs and Quality Affairs. For the past 3
years, Ms Desmet was Senior Manager of the Clinical Safety for the
international division at St. Jude Medical. She also worked as head
of the regulatory affairs and quality assurance for Kimberly-Clark
Healthcare where she contributed to the registration of several
medical devices across the world.
- Didier LeNormand joins Cellnovo
as interim CFO in replacement of Bart Bergstein who has left the
company. Mr. LeNormand has a long and distinguished career in
banking and finance having worked for, among others, BASF, Leica
and most recently Novagali Pharma (sold to Santem Pharma
Japan).
- Bommy Lee, is appointed Director
of Digital Marketing and Communications. Ms. Lee is a digital
marketing professional who previously had developed the digital
strategy and approaches for Mauna Kea Technologies, a medical
device firm. She has also worked at the International Herald
Tribune as Senior Producer and Editor.
- Thierry Lambert, is
appointed Director of Distributor Network for
Cellnovo. Mr. Lambert joins Cellnovo from LabStyle, a blood glucose
metering company. He has a strong experience of the diabetes field,
acquired at Medtronic, and later at Dexcom where he launched their
Continuous Blood Glucose device across Europe,
driving both marketing and distribution strategies and
partnerships.
“I am honored to succeed Eric and I want to personally thank him
for his tireless work in developing the Company, bringing the
Cellnovo technology to the market and his guidance over the
years ”, said Sophie Baratte, CEO. “We are thrilled to expand
the team that Eric built with these strategic hires which position
Cellnovo for continued growth.”
About Cellnovo
An independent medical technology company specialising in
diabetes, Cellnovo has developed and markets the first connected
all-in-one diabetes management system that helps make life easier
for patients. Compact, tubeless, intuitive and entirely connected,
Cellnovo’s insulin pump comprises a mobile touchscreen controller
with an integrated blood-glucose meter. This unique device allows
optimal management of insulin injections whilst ensuring extensive
freedom of movement and peace of mind for patients. Thanks to the
automatic transmission of data, it also allows the patient’s
condition to be continually monitored by family members and
healthcare professionals in real-time.
For further information please visit www.cellnovo.com
Cellnovo is listed on Euronext, Compartment CISIN: FR0012633360
– Ticker: CLNV
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151008006247/en/
CellnovoSophie
Baratteinvestors@cellnovo.comorNewCapInvestor
RelationEmmanuel Huynhcellnovo@newcap.fr+ 33 1 44 71 94
92orNewCapMedia RelationsNicolas
Merigeaucellnovo@newcap.fr+33 1 44 71 94 98